TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: mean maximum grade of radiation dermatitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: maximum Skindex-16 score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence of carotid artery puncture
Endpoint domain: Adverse events/effects
Primary endpoint: Overlap of IJV over CA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: two hour pain free rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intraoperative plasma concentrations of epinephrine and cortisol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Sevoflurane concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 30-day rates of rebleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: MNA score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: eating symptoms in patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: OxLDL-C levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: FAP values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Dentine tubule occlusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression of vascular calcification
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: lower frequency of neurological deterioration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: greater frequency of discharge to home
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: greater incidence of good long-term outcomes
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: 24 hour urine magnesium excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Functional Ability (FA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: early readmission
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: End-of-treatment response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: elbow pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: elbow function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Muscle glycogen utilization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: VAS score (dynamic pain and nausea)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lightheadedness
Endpoint domain: Adverse events/effects
Primary endpoint: surgical-site infection rates
Endpoint domain: Adverse events/effects
Primary endpoint: skin colonization levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: patient preference for dressing duration
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: blood flow (BF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fractional glucose extraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Overall survival at 90 days
Endpoint domain: Mortality/survival
Primary endpoint: persistent wheeze
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: episodes of troublesome lung symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: congenital malformations
Endpoint domain: Adverse events/effects
Primary endpoint: Ankle plantar flexor power
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Mean muscle thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective improvements in facial attributes
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Sildenafil exposure (AUC(infinity) geometric mean ratio)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean maximum changes in systolic and diastolic BP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: STD rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: match rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: D90 dose requirement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: V150 and V200 volumes of HR-cervix
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: daily physical activity level (steps/day)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 6-min walking test (6MWT) distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alleviation of hot flashes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in sleep condition
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Rates of tobacco sales to minors
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Occipito-Cervical Angle (OCI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EGFR inhibitor-induced rash
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: functional level
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Bone mineral density (BMD) improvement in lumbar area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in ionized calcium levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: false-positive rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: benign prostatic hyperplasia related health status
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: peak urinary flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum alanine aminotransferase activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Overall ophthalmic improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Activity Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in insulin resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: mean afebrile period
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: stay days in ICU
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Postoperative haematomas
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in the number of daily cigarettes smoked
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: event-free survival rate at 16 weeks
Endpoint domain: Mortality/survival
Primary endpoint: Difference in LVEF between acute and chronic phases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Root mean square intrasubject coefficient of variation in DLCO
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Incidence of dystocia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Consent rates
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Time taken to complete survey
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PaO2 changes during walking
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Mean percentage of days and nights without symptoms
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Mean hidden volume loss of RBC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mean total volume loss of RBC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mean visible volume loss of RBC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: rSBA titers ≥1:8 and ≥1:128
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: rSBA geometric mean titers (GMTs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Stent patency duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CYP3A activity (MR) decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(F) increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cl(m(6beta)) decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum levels of Apolipoprotein-A (APO-A)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum levels of High-Density Lipoprotein (HDL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Breast-feeding continuation at 3 months post partum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Exclusive breast-feeding at 3 months post partum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Satisfaction with feeding experience
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reduction of LDL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Expected satiety as a predictor of food choice
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Palatability as a predictor of food choice
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Injection site reactions after Tdap immunization
Endpoint domain: Adverse events/effects
Primary endpoint: Systemic symptoms after Tdap immunization
Endpoint domain: Adverse events/effects
Primary endpoint: Concentrations of pertussis antibodies at delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: mean time to re-epithelialization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of adverse treatment effects
Endpoint domain: Adverse events/effects
Primary endpoint: Neonatal morbidity
Endpoint domain: Adverse events/effects
Primary endpoint: Cerebral palsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Daily living skills scores
Endpoint domain: Life impact
Endpoint subdomain: Functional outcomes
Primary endpoint: FAAM change from baseline to 6-months
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Meal size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: snack intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Activity limitations
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Lymph node metastasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lymphatic system outcomes
Primary endpoint: ischaemic stroke
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Safety and tolerability of GS-9620
Endpoint domain: Adverse events/effects
Primary endpoint: Induction of chemokines/cytokines and IFN-stimulated genes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: gadolinium-enhanced lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: global outcomes
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: short-term adverse effects
Endpoint domain: Adverse events/effects
Primary endpoint: Pain at removal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reversal rate of fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: AST level decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: MCIC total IRLS cut-off score for clinical improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reduction in ABPM
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Level of urinary 8‐iso‐PGF2α
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Telomere methylation levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of CDMS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effect on primary outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PANSS total score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: proportion of good outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduction of depression symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to 90% block
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality-Adjusted Life Years (QALYs)
Endpoint domain: Physiological/clinical
Primary endpoint: Life-years
Endpoint domain: Mortality/survival
Primary endpoint: incidence of major adverse events (MAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Conversion to type 2 diabetes mellitus
Endpoint domain: Mortality/survival
Primary endpoint: Follow-up data submission rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Glycaemic index (GI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: mean relative rCBF changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Reduction in IPV exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SVAWS intervention effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CESD-R intervention effect
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Time from enrolment to last unformed stool
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Time to first formed stool
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Use of rescue albuterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Driving ability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: levels of cTn-I
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: time free from serious bacterial infections
Endpoint domain: Adverse events/effects
Primary endpoint: Lowering LDL-c
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Lowering Apo B
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Lowering ApoB/ApoA ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Vaginal delivery rates within 12 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Induction to vaginal delivery interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Uterine hyperstimulation rates
Endpoint domain: Adverse events/effects
Primary endpoint: Neutrophil number
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Total daily dose of propofol (ml/day)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of recurrence of venous thromboembolism
Endpoint domain: Mortality/survival
Primary endpoint: Four-year mortality rate
Endpoint domain: Mortality/survival
Primary endpoint: Spontaneous abortions
Endpoint domain: Mortality/survival
Primary endpoint: Functional difficulties in IADLs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 6-month outcomes
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Body image
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Sexual enjoyment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Micturition symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: proinsulin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: N-acetyl-beta-D-glucosaminidase (NAG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Serum fluoride
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Rates of bleeding within 24 hours of surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of reexploration within 24 hours of surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Amount of intra‐ and postoperative packed red blood cell (PRBC) transfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: spatial visualisation ability improvement
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: processing speed improvement
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: sprint power
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: peak aerobic power output
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCinf of roxadustat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of roxadustat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum EPO levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: markers of erythropoiesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: ease of defecation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: lowest overnight peak flow rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: objective improvement in sleep quality
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Sitting balance measured by CoP deviation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sitting balance measured by FIST score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: combined safety end point
Endpoint domain: Adverse events/effects
Primary endpoint: accuracy of PCT in diagnosing bacterial infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Total serum 25[OH]D levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: VISA-A scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: AUC(0-24) of E3174
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Agreement between telephone and in-person triage designations
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Estradiol concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Screening for psychological illness support
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reluctance to attend medical centre
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in metaplasia index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: hsTnT reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: sST2 reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: urinary cGMP increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Test scores at 1 and 7 weeks
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Maximal serum concentration (C max) of total and free RCT‐18
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean elimination half-life of total and free RCT‐18
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Substantial IgM reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Insulin-mediated whole-body nonoxidative glucose disposal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Muscle glycogen storage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Muscle pyruvate dehydrogenase complex activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: quantity of physiotherapy used
Endpoint domain: Resource use
Endpoint subdomain: Other resource use